Close this search box.

CEO Hanson leaving enGene

ARTICLE | Management Tracks

Plus: Compugen names Mahler CMO and updates from Merck, Navega, RAPT and Ocuphire

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst 

February 16, 2024 1:34 AM UTC

enGene Holdings Inc. (NASDAQ:ENGN) is looking for a new CEO following the resignation of Jason Hanson, who said he’ll depart the company for personal reasons as soon as a successor is named. Hanson joined enGene, which is developing a non-viral gene therapy to treat BCG-unresponsive non-muscle invasive bladder cancer, in 2018. 

Cancer immunotherapies company Compugen Ltd. (NASDAQ:CGEN; Tel Aviv:CGEN) hired Michelle Mahler as CMO, effective March 1, succeeding Henry Adewoye, who is leaving to pursue other opportunities. Mahler joined the company in October 2023 as VP of clinical development, before which she was CMO of 1E Therapeutics Ltd. …